Current methods for quantifying biological molecules often lack the sensitivity and specificity needed for early disease detection and personalized medicine. Traditional diagnostic approaches may struggle with the complexity of multi-omics data and the need for precise health surveillance tests.

Complete Omics specializes in multi-omics diagnostics, offering patented platforms for genomics, proteomics, and metabolomics that enable precise quantification of biological molecules. The company's platforms, including DEEPER-Seq for genomics and MT-SRM, SAFE-SRM, MANA-SRM, and Neo-True for proteomics, provide robust solutions for both basic research and clinical applications. Complete Omics addresses the need for sensitive and specific health surveillance tests by measuring different pools of biological molecules simultaneously. Their Valid-NEO platform is the only patented method in the U.S. capable of directly quantifying neoantigens on cell surfaces, supporting innovative drug development and companion diagnostics.

DEEPER-Seq Platform: Patented barcoded single-strand library with dual-RNA probe capture for genomics, suitable for FFPE, plasma, and damaged nucleic acid samples.

MT-SRM, SAFE-SRM, MANA-SRM, Neo-True Platforms: Leading quantitative proteomics platforms for TMT/iTRAQ relative quant, SRM/MRM/PRM absolute quant, neoantigen ID and quant, and more.

MetaBoost Chemical Derivatizations: Proprietary technology for extremely sensitive detection and quantification of small molecules in metabolomics.

Valid-NEO® Platform: Patented method for direct quantification of neoantigens on cell surfaces, enabling personalized medicine and drug development.

Complete360® Plasma Proteomics and Diagnostics: Clinical proteomics pipeline for personalized cancer therapeutics.

CompleteCohort® Large Cohort Multi-Omics: Multi-omics study services for large cohorts of samples.

Single Cell Omics: Single cell proteomics and genomics assays conducted by leading experts.

The primary customers are researchers, pharmaceutical companies, and healthcare providers seeking advanced diagnostic tools for personalized medicine, cancer research, and early disease detection.

Complete Omics generates revenue through clinical diagnostic services, research collaborations, and licensing of its patented multi-omics platforms. In December 2023, Complete Omics closed a $10 million Series A financing round.